Topoisomerase 1 Inhibition Promotes Cyclic GMP-AMP Synthase-Dependent Antiviral Responses

• Published in: mBio Vol. 8; no. 5
• Main Authors: Pépin, Geneviève, Nejad, Charlotte, Ferrand, Jonathan, Thomas, Belinda J, Stunden, H James, Sanij, Elaine, Foo, Chwan-Hong, Stewart, Cameron R, Cain, Jason E, Bardin, Philip G, Williams, Bryan R G, Gantier, Michael P
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 03.10.2017
• Subjects: Animals; Antigens, Viral, Tumor - genetics; Antigens, Viral, Tumor - immunology; Antiviral Agents - pharmacology; camptothecin; Camptothecin - pharmacology; Cell Line; cGAS; Coculture Techniques; DNA Damage; DNA Topoisomerases, Type I - drug effects; DNA Topoisomerases, Type I - metabolism; Fibroblasts - drug effects; Fibroblasts - virology; Humans; Immunity, Innate - drug effects; Inflammation; Mice; Nucleotides, Cyclic - metabolism; Observation; simian virus 40; Simian virus 40 - drug effects; Simian virus 40 - immunology; Simian virus 40 - physiology; STING; topoisomerase 1; Topoisomerase I Inhibitors - pharmacology; Virus Diseases - drug therapy; Virus Diseases - immunology; Virus Diseases - virology; cGAS; STING; simian virus 40; camptothecin; DNA damage; topoisomerase 1
• ISSN: 2161-2129; 2150-7511
• DOI: 10.1128/mBio.01611-17

Inflammatory responses, while essential for pathogen clearance, can also be deleterious to the host. Chemical inhibition of topoisomerase 1 (Top1) by low-dose camptothecin (CPT) can suppress transcriptional induction of antiviral and inflammatory genes and protect animals from excessive and damaging inflammatory responses. We describe the unexpected finding that minor DNA damage from topoisomerase 1 inhibition with low-dose CPT can trigger a strong antiviral immune response through cyclic GMP-AMP synthase (cGAS) detection of cytoplasmic DNA. This argues against CPT having only anti-inflammatory activity. Furthermore, expression of the simian virus 40 (SV40) large T antigen was paramount to the proinflammatory antiviral activity of CPT, as it potentiated cytoplasmic DNA leakage and subsequent cGAS recruitment in human and mouse cell lines. This work suggests that the capacity of Top1 inhibitors to blunt inflammatory responses can be counteracted by viral oncogenes and that this should be taken into account for their therapeutic development. Recent studies suggest that low-dose DNA-damaging compounds traditionally used in cancer therapy can have opposite effects on antiviral responses, either suppressing (with the example of CPT) or potentiating (with the example of doxorubicin) them. Our work demonstrates that the minor DNA damage promoted by low-dose CPT can also trigger strong antiviral responses, dependent on the presence of viral oncogenes. Taken together, these results call for caution in the therapeutic use of low-dose chemotherapy agents to modulate antiviral responses in humans.